

Silke Gillessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/357318/publications.pdf>

Version: 2024-02-01

174
papers

18,876
citations

17440

63
h-index

12946

131
g-index

185
all docs

185
docs citations

185
times ranked

17130
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	3.1	21
2	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
3	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
4	Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 244-258.	1.2	211
5	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	2.8	12
6	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	30.7	102
7	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. <i>British Journal of Cancer</i> , 2022, 126, 1140-1144.	6.4	23
8	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
9	Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 362-375.	1.2	74
10	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	18.7	173
11	Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. <i>Cancers</i> , 2022, 14, 1245.	3.7	19
12	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4
13	Prostate Cancer and Sleep Disorders: A Systematic Review. <i>Cancers</i> , 2022, 14, 1784.	3.7	5
14	Clinical trials for metastatic castrate-resistant prostate cancer—“who is looking after the control patients? Questions for the future. <i>Annals of Oncology</i> , 2022, 33, 574-577.	1.2	4
15	Letter to the Editor - Reply: Manuscript Number: EURUROL-D-22-00214 – Brief communication: What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, e13-e13.	1.9	2
16	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	1.9	33
17	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
18	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
20	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
21	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	2.8	14
22	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. <i>European Journal of Cancer</i> , 2022, 170, 285-295.	2.8	9
23	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	2.5	4
24	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
25	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2022, 5, 530-536.	5.4	20
26	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€™2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
27	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€™2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
28	When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. <i>European Urology</i> , 2021, 79, 565-567.	1.9	25
29	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	30.5	434
30	Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 550-558.	1.8	6
31	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571.	1.8	10
32	Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 555.	7.1	66
33	Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries. <i>JCO Global Oncology</i> , 2021, 7, 512-515.	1.8	2
34	In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions. <i>European Urology Open Science</i> , 2021, 26, 14-17.	0.4	2
35	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	5.4	23
36	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83

#	ARTICLE	IF	CITATIONS
37	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
38	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	5.4	26
39	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.4	2
40	Metastatic Prostate Cancer: In Search of More Granularity. <i>Journal of Clinical Oncology</i> , 2021, 39, 2968-2969.	1.6	4
41	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , 2021, 374, 216-224.	12.6	135
42	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102300.	7.7	8
43	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. <i>Nature Communications</i> , 2021, 12, 7033.	12.8	27
44	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	3.1	131
45	Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. <i>World Journal of Urology</i> , 2020, 38, 681-693.	2.2	12
46	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
47	The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. <i>Lancet Oncology</i> , The, 2020, 21, 17-19.	10.7	8
48	Precision Oncology for Metastatic Prostate Cancer: Translation into Practice. <i>European Urology</i> , 2020, 78, 771-774.	1.9	3
49	Current treatment options for locally advanced prostate cancer: EAU (-SIOG) guidelines view and recommendations. <i>European Urology Open Science</i> , 2020, 19, e1804-e1805.	0.4	0
50	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
51	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	1.9	110
52	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
53	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	1.6	37
54	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	1.9	101

#	ARTICLE	IF	CITATIONS
55	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	1.2	485
56	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
57	Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 77, 667-668.	1.9	44
58	Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100256.	1.7	10
59	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 285-293.	1.9	125
60	Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). <i>Cancers</i> , 2019, 11, 1099.	3.7	18
61	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	1.9	151
62	All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 302-308.	3.8	26
63	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	1.9	142
64	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	1.6	13
65	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. <i>Annals of Oncology</i> , 2019, 30, 1992-2003.	1.2	262
66	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e323-e328.	1.9	23
67	What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. <i>European Urology Focus</i> , 2019, 5, 162-164.	3.1	7
68	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	2.6	36
69	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 348-355.e5.	1.9	27
70	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.	1.6	42
71	Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. <i>Oncology Research and Treatment</i> , 2019, 42, 366-374.	1.2	10
72	Statins "No more cream for cancer. <i>European Journal of Cancer</i> , 2019, 112, 107-108.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1412-1423.	1.6	246
74	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	1.9	15
75	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 706-720.	1.2	750
76	EAU“ESMO consensus statements on the management of advanced and variant bladder cancer”an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	1.2	96
77	Management of Prostate Cancer Patients with Clinically Positive Lymph Nodes. <i>European Urology Oncology</i> , 2019, 2, 302-303.	5.4	0
78	Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. <i>BJU International</i> , 2019, 123, 826-833.	2.5	25
79	The Advanced Prostate Cancer Consensus on a regional level “ what can we learn?. <i>BJU International</i> , 2019, 123, 3-4.	2.5	0
80	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	1.9	8
81	TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?. <i>Clinical Cancer Research</i> , 2019, 25, 1699-1701.	7.0	4
82	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	1.9	278
83	Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5007-5007.	1.6	51
84	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	1.2	196
85	When and how to use carboplatin in metastatic castration-resistant prostate cancer?. <i>European Journal of Cancer</i> , 2018, 92, 96-99.	2.8	2
86	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
87	Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>Eur Urol</i> 2018;73:178-211. <i>European Urology</i> , 2018, 73, e32-e33.	1.9	6
88	Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. <i>European Urology</i> , 2018, 73, 316-321.	1.9	31
89	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	1.6	129
90	Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. <i>Journal of Clinical Oncology</i> , 2018, 36, 3381-3387.	1.6	49

#	ARTICLE	IF	CITATIONS
91	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
92	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2018, 392, 2353-2366.	13.7	901
93	Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer. <i>European Urology</i> , 2018, 74, 239-240.	1.9	0
94	Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. <i>Cell Reports</i> , 2018, 23, 2819-2831.e5.	6.4	36
95	Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 349-354.	1.9	11
96	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, 1658-1686.	1.2	228
97	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	1.8	44
98	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. <i>European Urology</i> , 2017, 72, 521-531.	1.9	174
99	Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 289-293.	3.9	43
100	Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy. <i>European Journal of Cancer</i> , 2017, 77, 127-139.	2.8	12
101	Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from “castration-resistant” prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 1692-1694.	1.2	4
102	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
103	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	1.6	56
104	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-200.	1.6	41
105	Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. <i>PLoS ONE</i> , 2017, 12, e0181557.	2.5	15
106	Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. <i>Annals of Oncology</i> , 2016, 27, 975-984.	1.2	76
107	Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. <i>Journal of Proteome Research</i> , 2016, 15, 1821-1829.	3.7	41
108	Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. <i>European Urology</i> , 2016, 70, 906-908.	1.9	51

#	ARTICLE	IF	CITATIONS
109	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	10.7	259
110	The oncologistsâ€™ unmet clinical needs for imaging in advanced prostate cancer. <i>Clinical and Translational Imaging</i> , 2016, 4, 423-431.	2.1	2
111	Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. <i>Proteomics</i> , 2015, 15, 3711-3721.	2.2	44
112	Restless Legs Syndromeâ€™ An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e385-e386.	1.9	5
113	On Nonharming: The Debate Continues in Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2319-2320.	1.6	2
114	Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e205-e208.	1.9	28
115	Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. <i>Nature Medicine</i> , 2015, 21, 407-413.	30.7	358
116	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	1.2	279
117	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v69-v77.	1.2	346
118	Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 167-172.	3.9	12
119	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015, 26, 833-838.	1.2	57
120	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015, 67, 904-912.	1.9	18
121	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinomaâ€™ Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
122	Reply to the letter to the editor â€™ Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015â€™ by GillesSEN et al.. <i>Annals of Oncology</i> , 2015, 26, 2354-2355.	1.2	13
123	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancerâ€™ going beyond PSA and imaging, a systematic literature review. <i>Annals of Oncology</i> , 2015, 26, 2221-2247.	1.2	10
124	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	7.0	36
125	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014, 111, 2248-2253.	6.4	52
126	Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). <i>European Urology</i> , 2014, 66, 468-474.	1.9	100

#	ARTICLE	IF	CITATIONS
127	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	2.8	133
128	Management of von Hippel-Lindau Disease: An Interdisciplinary Review. <i>Oncology Research and Treatment</i> , 2014, 37, 761-771.	1.2	47
129	Treatment sequencing in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 426.	1.6	41
130	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	1.2	137
131	Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). <i>European Urology</i> , 2013, 64, 150-158.	1.9	120
132	2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. <i>Annals of Oncology</i> , 2012, 23, 59-64.	1.2	126
133	Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07). <i>Clinical Cancer Research</i> , 2012, 18, 6049-6057.	7.0	36
134	First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). <i>Annals of Oncology</i> , 2012, 23, 531-536.	1.2	68
135	Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. <i>Case Reports in Oncology</i> , 2012, 5, 280-289.	0.7	8
136	Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. <i>European Urology</i> , 2011, 60, 1235-1243.	1.9	49
137	Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients. <i>Oncology Research and Treatment</i> , 2011, 34, 59-64.	1.2	24
138	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3342-3347.	7.1	175
139	Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. <i>Annals of Oncology</i> , 2011, 22, 815-820.	1.2	2
140	Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1760-1770.	6.3	77
141	Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. <i>Annals of Oncology</i> , 2010, 21, 1589-1593.	1.2	12
142	Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib. <i>Diabetes Care</i> , 2010, 33, e82-e82.	8.6	11
143	Concordant colon tumors in monozygotic twins previously treated for prostate cancer. <i>Familial Cancer</i> , 2009, 8, 167-171.	1.9	5
144	Metastatic bone pain: treatment options with an emphasis on bisphosphonates. <i>Supportive Care in Cancer</i> , 2008, 16, 1105-1115.	2.2	64

#	ARTICLE	IF	CITATIONS
145	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. European Urology, 2008, 53, 478-496.	1.9	488
146	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 2008, 53, 497-513.	1.9	243
147	Prevention of Docetaxel- or Paclitaxel-Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo-Controlled, Double-Blind Study. Oncologist, 2008, 13, 337-346.	3.7	58
148	Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Annals of Oncology, 2008, 19, 824-825.	1.2	54
149	Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulinitis and destruction of β cells. Blood, 2007, 110, 954-961.	1.4	25
150	A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British Journal of Cancer, 2007, 97, 1480-1485.	6.4	100
151	Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology, Immunotherapy, 2006, 55, 1524-1533.	4.2	104
152	A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemotherapy and Pharmacology, 2006, 57, 533-539.	2.3	57
153	CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Experimental Dermatology, 2005, 14, 250-258.	2.9	43
154	Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate, 2005, 64, 323-331.	2.3	9
155	Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 316-320.	3.9	70
156	Von Hippel-Lindau Disease " a Rare Disease Important to Recognize. Oncology Research and Treatment, 2005, 28, 159-163.	1.2	11
157	Capecitabine in hormone-resistant metastatic prostatic carcinoma " a phase II trial. British Journal of Cancer, 2004, 90, 1312-1317.	6.4	40
158	Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. Journal of Immunological Methods, 2004, 287, 109-124.	1.4	74
159	Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology, 2004, 63, 778-780.	1.0	80
160	CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103, 1595-1601.	1.4	219
161	Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2003, 21, 3343-3350.	1.6	278
162	Deficiencies of GM-CSF and Interferon β Link Inflammation and Cancer. Journal of Experimental Medicine, 2003, 197, 1213-1219.	8.5	162

#	ARTICLE	IF	CITATIONS
163	CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8874-8879.	7.1	89
164	The Proteasome, a New Target for Cancer Therapy. <i>Oncology Research and Treatment</i> , 2002, 25, 534-539.	1.2	21
165	Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. <i>Blood</i> , 2002, 100, 1354-1361.	1.4	451
166	Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity. <i>Blood</i> , 2001, 97, 922-928.	1.4	36
167	Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. <i>Blood</i> , 2001, 97, 1435-1441.	1.4	18
168	Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. <i>Blood</i> , 2001, 97, 1442-1450.	1.4	74
169	Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. <i>Cancer Research</i> , 2001, 61, 162-71.	0.9	76
170	Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. <i>Cancer Research</i> , 2000, 60, 3239-46.	0.9	342
171	Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex. <i>Journal of Immunology</i> , 1998, 160, 2174-9.	0.8	44
172	Interleukin-12 Antagonist Activity of Mouse Interleukin-12 p40 Homodimer <i>in Vitro</i> and <i>in Vivo</i> . <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 1-12.	3.8	137
173	Evidence for Multiple Sites of Interaction between IL-12 and Its Receptor. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 390-393.	3.8	17
174	Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. <i>European Journal of Immunology</i> , 1995, 25, 200-206.	2.9	431